Epizyme President of Research and Chief Scientific Officer, Robert Copeland, Announces Retirement from the Company
March 09, 2017 06:30 ET
|
Epizyme, Inc.
CAMBRIDGE, Mass., March 09, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that President of...
Epizyme Announces 2016 Fourth Quarter and Full-Year Results Conference Call Date and March Investor Conferences
February 27, 2017 09:06 ET
|
Epizyme, Inc.
CAMBRIDGE, Mass., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will...
Epizyme Elects Kevin Conroy to its Board of Directors
February 07, 2017 06:30 ET
|
Epizyme, Inc.
CAMBRIDGE, Mass., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that the Company has...
Epizyme to Present at Upcoming Investor Conferences
February 02, 2017 06:30 ET
|
Epizyme, Inc.
CAMBRIDGE, Mass., Feb. 02, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that the Company will...
Epizyme Announces Presentation at J.P. Morgan 35th Annual Healthcare Conference
January 03, 2017 06:30 ET
|
Epizyme, Inc.
CAMBRIDGE, Mass., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that Robert Bazemore,...
Epizyme Announces Fast Track Designation for Tazemetostat in DLBCL and Provides Solid Tumor Program Update
November 28, 2016 06:30 ET
|
Epizyme, Inc.
FDA Grants Tazemetostat Fast Track Designation for DLBCL with EZH2 Activating Mutations Company Focuses Phase 2 Solid Tumor Study on INI1-Negative Tumors and Expands Epithelioid Sarcoma Cohort ...
Epizyme President of Research and Chief Scientific Officer Named AAAS Fellow
November 21, 2016 11:00 ET
|
Epizyme, Inc.
CAMBRIDGE, Mass., Nov. 21, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that President of...
Epizyme Provides Update on Execution of Clinical Program and Reports Third Quarter 2016 Financial Results
November 03, 2016 06:30 ET
|
Epizyme, Inc.
Robust Clinical Program Underway for Tazemetostat in Multiple Cancer Indications and Treatment Settings as Both Monotherapy and Combination Agent Conference Call to Be Held Today at 8:30 a.m....
Epizyme Expands Clinical Programs through Cooperative Research and Development Agreements with the National Cancer Institute
October 31, 2016 06:30 ET
|
Epizyme, Inc.
CAMBRIDGE, Mass., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that it has entered...
Epizyme to Report Business Highlights and Third Quarter 2016 Financial Results on November 3, 2016
October 27, 2016 06:30 ET
|
Epizyme, Inc.
CAMBRIDGE, Mass., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management...